scholarly journals Botulinum toxin for treatment of Raynaud phenomenon in CREST syndrome

2018 ◽  
Vol 24 (12) ◽  
Author(s):  
Juliana Berk-Krauss ◽  
Mitalee P Christman ◽  
Andrew Franks ◽  
Kristen Lo Sicco ◽  
Tracey N Liebman
Keyword(s):  
Botulinum Toxin ◽  
Crest Syndrome ◽  
Raynaud Phenomenon

scholarly journals New trends in botulinum toxin use in dermatology

2018 ◽  
pp. 277-282 ◽  
Author(s):  
Stefania Guida ◽  
Francesca Farnetani ◽  
Steven P. Nisticò ◽  
Caterina Giorgio Mariarosaria ◽  
Graziella Babino ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Neurotoxin ◽  
Current Knowledge ◽  
Hypertrophic Scars ◽  
Skin Disorders ◽  
Facial Flushing ◽  
Cutaneous Lesions ◽  
Raynaud Phenomenon ◽  
Skin Conditions ◽  
Review Current

Background: Recent studies have highlighted new botulinum neurotoxin (BoNT) applications in the field of dermatology. Objective: To review current knowledge of BoNT use in dermatology. Methods: The literature of the last 5 years has been reviewed. Results: We describe interesting protocols of BoNT treatment for hyperhidrosis (HH), hypertrophic scars and keloids, Raynaud phenomenon, facial flushing, oily skin, psoriasis, Hailey-Hailey disease, and cutaneous lesions like painful lesions and periorbital syringomas. Conclusions: Several skin conditions eligible for BoNT treatment have been described. After the wide application for HH treatment, scars as well as vascular and inflammatory skin disorders, oily skin and cutaneous lesions represent fields of application of BoNT.

scholarly journals Reply to “Interdigital injection of botulinum toxin for patients with Raynaud phenomenon”

2020 ◽  
Vol 83 (6) ◽  
pp. e411
Author(s):  
Lucía Quintana-Castanedo ◽  
Marta Feito-Rodríguez ◽  
Raúl De Lucas-Laguna
Keyword(s):  
Botulinum Toxin ◽  
Raynaud Phenomenon

scholarly journals Reply to: “Interdigital injection of botulinum toxin for patients with Raynaud phenomenon”

2020 ◽  
Vol 83 (6) ◽  
pp. e409-e410
Author(s):  
Charlotte Jaloux ◽  
Najib Kachouh ◽  
Régis Legré ◽  
Florent Amatore ◽  
Alice Mayoly
Keyword(s):  
Botulinum Toxin ◽  
Raynaud Phenomenon

Botulinum Toxin for the Treatment of Intractable Raynaud Phenomenon

2021 ◽  
Vol 46 (1) ◽  
pp. 54-59
Author(s):  
Jose E. Gallegos ◽  
Dani C. Inglesby ◽  
Zachary T. Young ◽  
Fernando A. Herrera
Keyword(s):  
Botulinum Toxin ◽  
Raynaud Phenomenon

scholarly journals New trends in botulinum toxin use in dermatology

2019 ◽  
pp. 277-282
Author(s):  
Stefania Guida ◽  
Francesca Farnetani ◽  
Steven Nisticò ◽  
Caterina Giorgio Mariarosaria ◽  
Graziella Babino ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Neurotoxin ◽  
Current Knowledge ◽  
Hypertrophic Scars ◽  
Skin Disorders ◽  
Facial Flushing ◽  
Cutaneous Lesions ◽  
Raynaud Phenomenon ◽  
Skin Conditions ◽  
Review Current

Background: Recent studies have highlighted new botulinum neurotoxin (BoNT) applications in the field of dermatology. Objective: To review current knowledge of BoNT use in dermatology. Methods: The literature of the last 5 years has been reviewed. Results: We describe interesting protocols of BoNT treatment for hyperhidrosis (HH), hypertrophic scars and keloids, Raynaud phenomenon, facial flushing, oily skin, psoriasis, Hailey-Hailey disease, and cutaneous lesions like painful lesions and periorbital syringomas. Conclusions: Several skin conditions eligible for BoNT treatment have been described. After the wide application for HH treatment, scars as well as vascular and inflammatory skin disorders, oily skin and cutaneous lesions represent fields of application of BoNT.

scholarly journals Botulinum toxin in the treatment of Raynaud phenomenon in patients with systemic sclerosis

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Ruyi Cai ◽  
Zixi Yi ◽  
Ting Li ◽  
Rong Mu
Keyword(s):  
Botulinum Toxin ◽  
Systemic Sclerosis ◽  
Raynaud Phenomenon

Bilateral calcinosis cutis of orbital walls in CREST syndrome

2019 ◽  
Vol 4 (2) ◽  
pp. NP1-NP4
Author(s):  
Hadi Ghadimi ◽  
Mojgan Nikdel ◽  
Bahram Eshraghi
Keyword(s):  
Systemic Sclerosis ◽  
Surgical Excision ◽  
Crest Syndrome ◽  
Esophageal Dysmotility ◽  
Raynaud Phenomenon ◽  
Calcinosis Cutis ◽  
Subcutaneous Nodules ◽  
Close Proximity ◽  
Drug History

Purpose: To describe a patient with systemic sclerosis who presented with subcutaneous yellow–white nodules on her lateral orbital rims. Methods: Case report. Results: A 53-year-old female was referred for management of subcutaneous firm nodules on her lateral orbital rims. She was known to have CREST (calcification, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome, a limited variant of systemic sclerosis. Her drug history included diltiazem, captopril, aspirin, and prednisolone. There were bilateral multiple immobile yellow–white subcutaneous nodules with firm consistency, a few of which were in close proximity of periorbital skin. She was scheduled for surgical resection of the lesions and following tissue dissection, the calcified foci were removed. The incisions healed with some delay but the final postoperative follow-up at third month showed satisfactory appearance. Conclusion: Dystrophic calcinosis cutis occurs in approximately one-fourth of patients with systemic sclerosis (scleroderma), particularly in those with the limited variant or CREST syndrome. The most frequently involved sites are the extremities. Occasionally, calcinosis involves the trunk or head, but involvement of bony orbital walls is extremely rare. Surgical excision can be considered for treatment of discrete foci of calcinosis cutis.

The Role of Botulinum Toxin A in the Treatment of Raynaud Phenomenon

2016 ◽  
Vol 77 (3) ◽  
pp. 318-323 ◽  
Author(s):  
Francesco Segreto ◽  
Giovanni Francesco Marangi ◽  
Vincenzo Cerbone ◽  
Paolo Persichetti
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Toxin A ◽  
Raynaud Phenomenon
Sign in / Sign up

Export Citation Format

Share Document